(Press-News.org) A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.
Fred MacDonnell, professor of chemistry and biochemistry at The University of Texas at Arlington, has been researching a new generation of metal-based antitumor agents along with a team from the City of Hope Comprehensive Center Center in Duarte, Calif. Their aim is to find new therapies to complement widely used platinum-based therapies, such as cisplatin. Cisplatin is one of the most widely used anti-cancer drugs and shows remarkable effectiveness against some cancers, however it does not work on all cancers and can have severe side effects.
In a study published in the May edition of Molecular Cancer Therapeutics, the team describes two newly developed ruthenium polypyridyl complexes, or RPCs, that yielded results comparable to cisplatin against human non-small cell lung cancer cells in pre-clinical lab tests.
Unlike cisplatin, the RPCs were generally cleared from the body unchanged, without noticeable effects on metabolism or kidney function. In lab tests, healthy cells could withstand almost 10 times as much exposure to the team's ruthenium complexes as the cancer cells.
The study also found that the RPCs seemed to target cells in hypoxic states. Hypoxia, or low oxygen, is a signature of tumor cells.
"Cancer drugs on the market now generally are less effective under hypoxic conditions or insensitive to the oxygen concentration," MacDonnell said. "Since many tumor cells are under hypoxic stress and most normal cells are not, having something that becomes even more effective under hypoxia could have some real benefit to the patient."
The effectiveness of the RPCs tested seems to be associated with a particular portion of their structure. This portion, known as "tatpp" is redox-active, which means it is reduced when bound to DNA in the normal cellular environment. MacDonnell's team believe that this reduction step in the DNA bound compound sets in motion a biological process that triggers apoptosis, also known as programmed cell death, in cancer cells. Under hypoxic conditions, this reduction is more prevalent, leading to greater cell death in those cells.
"Being activated under low-oxygen conditions makes these unique complexes excellent candidates for use on some of the most difficult to treat tumors," said Dr. Sanjay Awasthi, professor of medical oncology and therapeutics research at City of Hope. "Now that we have demonstrated the role of the tatpp ligand in these biological processes, our team can continue toward the goal of using ruthenium-based complexes to enhance current treatments."
MacDonnell said the ruthenium complexes' increased effectiveness against malignant cells could be because the complexes can more easily enter cancer cells, which tend to be more metabolically active than normal cells. That hypothesis, however, is something the team will explore with further research.
INFORMATION:
The paper, called "Regression of lung cancer by hypoxia-sensitizing ruthenium polypridyl complexes," is available online at: http://mct.aacrjournals.org/content/12/5/643.short?rss=1&co=f000000009816s-1158206718. Grants from the National Institutes of Health's National Cancer Institute and the Robert A. Welch Foundation supported the work.
Besides MacDonnell and Awasthi, co-authors are: Abhishek Yadav, Thamara Janaratne, Adam S. Dayoub and Arthi Krishnan, of the UT Arlington chemistry/biochemistry department; Doyle H. Hawkins, of the UT Arlington math department; and Sharad S. Singhal and Sushma Yadav, of the City of Hope Comprehensive Cancer Center.
MacDonnell's work is representative of the scientific advances under way at The University of Texas at Arlington, a comprehensive research institution of more than 33,200 students and more than 2,200 faculty members in the heart of North Texas. Visit http://www.uta.edu to learn more.
New ruthenium complexes target cancer cells without typical side effects
2013-05-28
ELSE PRESS RELEASES FROM THIS DATE:
Shape-shifting nanoparticles flip from sphere to net in response to tumor signal
2013-05-28
Scientists at the University of California, San Diego, have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into netlike structures that accumulate at the site of a cancer, the team reports in the journal Advanced Materials this week.
Targeting treatments specifically to cancerous or other diseased cells depends on some means of accumulating high levels of a drug or other therapeutic ...
For pundits, it's better to be confident than correct
2013-05-28
PULLMAN, Wash. - It would be nice to think the pundits we see yelling on TV and squawking on Twitter are right all the time. It turns out they're wrong more often than they are right.
Now two Washington State University economics students have demonstrated that it simply doesn't pay as much for a pundit to be accurate as it does to be confident. It's one thing to be a good pundit, but another to be popular.
"In a perfect world, you want to be accurate and confident," says Jadrian Wooten. "If you had to pick, being confident will get you more followers, get you more demand."
Wooten ...
Saturated fats do not yield better bacon
2013-05-28
A recent paper published in the Journal of Animal Science suggests producers may want to adjust pig diets when including distillers dried grains with solubles (DDGS). Some producers believe that feeding pigs saturated fats will undo the fat-softening effects of DDGS. Firmer fat means longer-lasting pork.
But researchers from the University of Illinois found that including saturated fats in DDGS diets makes no difference in fat quality.
The researchers formulated six corn-soybean meal diets to test the effects of saturated fat additives on carcass fat quality in pigs. ...
Annals of Internal Medicine tip sheet for May 28, 2013
2013-05-28
1. Evidence Suggests Screening for Gestational Diabetes Can Improve Maternal and Fetal Outcomes
Evidence review will inform recommendations on screening for gestational diabetes
The oral glucose challenge test (OGCT) and testing for fasting plasma glucose levels may be the best way to rule out gestational diabetes mellitus (GDM) in women who are at about 24 weeks' gestation. The OGCT may be better for diagnosing women who have GDM. GDM puts babies at risk for having a high birth weight, low blood sugar, and jaundice. GDM is also associated with seizures or still birth. ...
UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies
2013-05-28
Irvine, CA & Seattle, WA — Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance.
The findings published the week of May 27 in the Proceedings of the National Academy of Sciences reveal that ShK-186 selectively blocks the activity of a protein that promotes inflammation through the Kv1.3 potassium channel. The study presents the first evidence that the drug candidate – which in March showed ...
KISS ME DEADLY proteins may help improve crop yields
2013-05-28
Dartmouth College researchers have identified a new regulator for plant hormone signaling -- the KISS ME DEADLY family of proteins (KMDs) – that may help to improve production of fruits, vegetables and grains.
The study's results will be published the week of May 27 in the journal Proceedings of the National Academy of Sciences. Journalists can access the paper, titled "SCFKMD controls cytokinin signaling by regulating the degradation of type-B response regulators," through EurekAlert!.
Professor G. Eric Schaller, the paper's senior author, studies the molecular mechanisms ...
Spine function improves following cell replacement therapy with fetal human stem cells
2013-05-28
Human foetal stem cell grafts improve both motor and sensory functions in rats suffering from a spinal cord injury, according to research published this week in BioMed Central's open access journal Stem Cell Research and Therapy. This cell replacement therapy also improves the structural integrity of the spine, providing a functional relay through the injury site. The research gives hope for the treatment of spinal cord injuries in humans.
Grafting human neural stem cells into the spine is a promising approach to promote the recovery of function after spinal injury. ...
Patients with end-stage kidney disease have different expectations than their doctors
2013-05-28
BOSTON – In any given year, 400,000 Americans suffering from end-stage kidney disease will undergo dialysis, and as many as 20 to 25 percent of those dialysis patients will die, a statistic comparable to many types of cancer. But while cancer doctors may be more accustomed to talking with patients about the likely course of their disease, a new study from Beth Israel Deaconess Medical Center finds that doctors who treat patients with kidney failure are reluctant to discuss a difficult prognosis, and their patients are likely to have distorted expectations about their own ...
All in one shot
2013-05-28
Boston, MA – Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges—one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens. This common sugar molecule makes it a promising target for the development of a broad-spectrum vaccine that can protect against numerous deadly microbes expressing this sugar on ...
When doctors and patients share in decisions, hospital costs go up
2013-05-28
Since the 1980s, doctors and patients have been encouraged to share decision making. Proponents argue that this approach promotes doctor-patient communication, enhances patient satisfaction, improves health outcomes, and even may lower cost.
Yet, a hospital-based study found that patients who want to participate in their medical decisions end up spending more time in the hospital and raising costs of their hospital stay by an average of $865.
The findings, published in JAMA Internal Medicine, came from the first hospital-based study to examine how patients' desire ...